These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 24511108)
1. Genetic alterations and personalized medicine in melanoma: progress and future prospects. Griewank KG; Scolyer RA; Thompson JF; Flaherty KT; Schadendorf D; Murali R J Natl Cancer Inst; 2014 Feb; 106(2):djt435. PubMed ID: 24511108 [TBL] [Abstract][Full Text] [Related]
2. [Molecular alterations in melanoma and targeted therapies]. Mourah S; Lebbé C Bull Cancer; 2014 Dec; 101 Suppl 2():S5-S11. PubMed ID: 25776766 [TBL] [Abstract][Full Text] [Related]
3. Main clues in the pathologic diagnosis of melanoma: is molecular genetics helping? Ferrara G; Senetta R; Paglierani M; Massi D Dermatol Ther; 2012; 25(5):423-31. PubMed ID: 23046021 [TBL] [Abstract][Full Text] [Related]
6. Melanoma genetics: the other side. Bis S; Tsao H Clin Dermatol; 2013; 31(2):148-55. PubMed ID: 23438378 [TBL] [Abstract][Full Text] [Related]
7. [Therapeutic approaches in Melanoma - a paradigm for personalized medicine]. Dummer R; Goldinger S; Rinderknecht J; Eggmann N; Felderer L; Braun R; French LE Praxis (Bern 1994); 2012 Jul; 101(15):955-9. PubMed ID: 22811327 [TBL] [Abstract][Full Text] [Related]
8. New drug targets in metastatic melanoma. Homet B; Ribas A J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077 [TBL] [Abstract][Full Text] [Related]
9. Major therapeutic developments and current challenges in advanced melanoma. Sullivan RJ; Flaherty KT Br J Dermatol; 2014 Jan; 170(1):36-44. PubMed ID: 24443912 [TBL] [Abstract][Full Text] [Related]
10. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747 [TBL] [Abstract][Full Text] [Related]
11. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166 [TBL] [Abstract][Full Text] [Related]
12. BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty KT; McArthur G Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085 [TBL] [Abstract][Full Text] [Related]
13. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474 [TBL] [Abstract][Full Text] [Related]
14. Oncogenetics of melanoma: basis for molecular diagnostics and therapy. Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632 [TBL] [Abstract][Full Text] [Related]
15. Successes and limitations of targeted cancer therapy in melanoma. Romano E; Michielin O Prog Tumor Res; 2014; 41():78-88. PubMed ID: 24727988 [TBL] [Abstract][Full Text] [Related]
16. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? Arnedos M; Vielh P; Soria JC; Andre F J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621 [TBL] [Abstract][Full Text] [Related]